Evidence-based management of Raynaud's phenomenon. (December 2017)

• Record Type: Journal Article
• Authors: Herrick, Ariane L.
• Is Part Of: Therapeutic advances in musculoskeletal disease. Volume 9:Number 12(2017)
• Page Start: 317
• Page End: 329
• Publication Date: 2017-12
• Subjects: critical ischaemia -- digital ulceration -- Raynaud's phenomenon -- systemic sclerosis -- treatment; Musculoskeletal system -- Diseases -- Periodicals; Musculoskeletal Diseases -- Periodicals; 616.7
• DOI: 10.1177/1759720X17740074
• Languages: English
• ISSNs: 1759-720X

Abstract

Raynaud's phenomenon (RP) is relevant to the rheumatologist because it may signify an underlying connective tissue disease and also because it can be very challenging to treat, especially when it has progressed to digital ulceration or critical ischaemia. This review article discusses diagnosis (does this patient have an underlying connective tissue disease?), including the role for nailfold capillaroscopy, and treatment. Management of 'uncomplicated' RP is first described and then treatment of RP complicated by progression to digital ulceration or critical ischaemia, highlighting recent advances (including phosphodiesterase type 5 inhibition, and endothelin 1 receptor antagonism) and the evidence base underpinning these. Possible future therapies are briefly discussed.